Literature DB >> 25908107

L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling.

Masaaki Ichinoe1, Nobuyuki Yanagisawa2, Tetuo Mikami3, Kiyomi Hana4, Norihiro Nakada2, Hitoshi Endou4, Isao Okayasu5, Yoshiki Murakumo2.   

Abstract

L-Type amino acid transporter 1 (LAT1) is one of the major amino acid transporters. High levels of LAT1 expression have been reported in various tumors, which can act as a novel prognostic marker. Previously, we demonstrated that LAT1 is highly expressed in advanced gastric carcinoma with lymph node metastasis, and proposed that LAT1 is an independent prognostic factor in non-scirrhous gastric carcinoma. The aim of the present study was to investigate the relationship between LAT1 expression and the size of lymph node metastatic lesions in gastric carcinoma. LAT1 and Ki-67 expression was immunohistochemically analyzed in 64 cases of advanced gastric carcinoma with lymph node metastasis. LAT1 expression in the metastatic lymph nodes was correlated with that in the primary lesions. The high LAT1 expression group showed a larger size of metastatic lesion and a higher Ki-67 labeling index than the low LAT1 expression group. LAT1 expression had a weak association with Ki-67 labeling index and tumor diameter of lymph nodes. These results suggest that LAT1 expression is associated with disease progression in gastric carcinoma. We proposed that LAT1 could be a potential therapeutic target for gastric carcinoma cases with large lymph node metastasis.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Gastric carcinoma; L-type amino acid transporter 1; Lymph node metastasis

Mesh:

Substances:

Year:  2015        PMID: 25908107     DOI: 10.1016/j.prp.2015.03.007

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Characteristics of 18F-FDG and 18F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1.

Authors:  Taesik Yun; Yoonhoi Koo; Sanggu Kim; Wonguk Lee; Hakhyun Kim; Dongwoo Chang; Soochong Kim; Mhan-Pyo Yang; Byeong-Teck Kang
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

Review 2.  Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment.

Authors:  Keitaro Hayashi; Naohiko Anzai
Journal:  World J Gastrointest Oncol       Date:  2017-01-15

3.  Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Keisuke Enomoto; Muneki Hotomi
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

4.  Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.

Authors:  Kosuke Higuchi; Shinichi Sakamoto; Keisuke Ando; Maihulan Maimaiti; Nobushige Takeshita; Kentaro Okunushi; Yoshie Reien; Yusuke Imamura; Tomokazu Sazuka; Kazuyoshi Nakamura; Jun Matsushima; Tomomi Furihata; Yuzuru Ikehara; Tomohiko Ichikawa; Naohiko Anzai
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

Review 5.  The Harmonious Interplay of Amino Acid and Monocarboxylate Transporters Induces the Robustness of Cancer Cells.

Authors:  Go J Yoshida
Journal:  Metabolites       Date:  2021-01-02

Review 6.  Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.

Authors:  Xue Zhao; Shinichi Sakamoto; Maihulan Maimaiti; Naohiko Anzai; Tomohiko Ichikawa
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

7.  CircARID1A binds to IGF2BP3 in gastric cancer and promotes cancer proliferation by forming a circARID1A-IGF2BP3-SLC7A5 RNA-protein ternary complex.

Authors:  Qiang Ma; Feifei Yang; Bo Huang; Xiaojuan Pan; Wei Li; Ting Yu; Xiaolin Wang; Lingyu Ran; Kun Qian; Hui Li; Haiping Li; Yuying Liu; Ce Liang; Junwu Ren; Yuying Zhang; Shimin Wang; Bin Xiao
Journal:  J Exp Clin Cancer Res       Date:  2022-08-19

8.  Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines.

Authors:  Gina Abdelaal; Andrew Carter; Mihalis I Panayiotides; David Tetard; Stephany Veuger
Journal:  Front Mol Biosci       Date:  2022-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.